Showing results (511-520 of 592) with videos related to
Sort By:
Pageof 60
Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 studyValentina Guarneri, Franco Bassan, Vittorina Zagonel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.Journal of Cachexia, Sarcopenia and Muscle|October 23, 2024
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational studyIlaria Trestini, Lorenzo Belluomini, Alessandra Dodi, et al.JCO Precision Oncology|October 7, 2024
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 ProgramAntonio Vitale, Luca Mastrantoni, Jacopo Russo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2026
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancerMaria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolè, et al.Pageof 60